VMT Scientific, Inc. Announces Funding
December 07 2005 - 6:00AM
PR Newswire (US)
LAS VEGAS, Dec. 7 /PRNewswire-FirstCall/ -- VMT Scientific Inc.
(OTC: VMTF) is proud to announce that it has secured funding that
will empower us to remain focused with respect in achieving proper
efficacy testing of the VasCir(TM) device. After assessing our
Phase II financial needs and developing a cost analysis, we are
confident that these funds will enable us to execute and achieve
our objectives as defined for Phase II. As always, we extend an
invitation to view our website http://www.vmtf.org/ so as to have a
clear understanding of our focus and technology. This Press Release
contains forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should not place undue reliance on these
forward-looking statements. These statements involve risks and
uncertainties that could cause actual results to differ materially
from those suggested in the forward- looking statements,
particularly those risks and uncertainties inherent in the process
of developing, manufacturing and distributing medical products and
Clinical trials. Factors that may cause such a difference include
risks related to VMT Scientific Inc.'s limited operating history,
risks associated with completing development and obtaining FDA
medical approvals, successful patent protection and prosecution,
successful sale of licensed technology nationally or
internationally. VMT Scientific technology will not meet with
market acceptance, the risk of future warranty and product
liability claims, the uncertainty of VMT Scientific Inc.'s future
access to capital to sustain operations, achieve profitability or
continue as a going concern, the failure by VMT Scientific Inc.'s
to secure and maintain relationships with suppliers, manufacturers
and other third parties, reliance on key employees, and dependence
on intellectual property. These forward-looking statements are
based on information and management's expectations as of the date
hereof. Future results may differ materially from our current
expectations. DATASOURCE: VMT Scientific Inc. CONTACT: Catherine S.
Ratelle, Director of Operations, VMT Scientific, Inc.,
+1-702-990-3477, Web site: http://www.vmtf.org/
Copyright